Literature DB >> 10342701

The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda.

P Waibale1, S J Bowlin, E A Mortimer, C Whalen.   

Abstract

BACKGROUND: Measles is an important public health problem in developing nations and there is concern that immune response to measles vaccination may be compromised by paediatric human immunodeficiency virus (HIV) infection. Therefore, this study investigated the relationship of immunoglobulin-G (Ig-G) antibody levels in children vaccinated against measles and HIV-1 infection. Further analysis was done to assess the influence of nutritional status on this relationship.
METHODS: The authors measured HIV and measles antibodies in 243 vaccinated children aged 17-41 months from Kampala, Uganda. Children were from paediatric and HIV clinics. Potential confounders of this relationship included nutritional anthropometric measures, age at and time since vaccination, measles exposure, family crowding, vaccination clinic and gender. Univariable and multivariable analyses were used to study these associations.
RESULTS: Fifty children (21%) were HIV infected. In univariable analysis, low measles antibody (<15 ELISA units/ml) was associated with HIV (P = 0.05; odds ratio (OR) = 1.86) and stunting (P = 0.06; OR = 1.68). Stunting, measured as height-for-age and defined as <-2 standard deviations of the reference population median, was a surrogate for chronic malnutrition. HIV was strongly associated with stunting (P = 0.0001; OR = 6.62). In multiple logistic regression, HIV was not associated with low measles antibodies; however, stunting (P = 0.04; OR = 1.81), and <3 children in the home (P = 0.01; OR = 1.96) were. Conversely, being male (P = 0.05; OR = 0.58), and measles in the home in the previous month (P = 0.04; OR = 0.33) were associated with high antibody levels.
CONCLUSIONS: These findings suggest that HIV in Ugandan children immunized for measles may indirectly interfere with measles antibody levels by causing malnutrition, the latter being the direct cause. Programmes to improve childhood nutrition, especially for HIV-infected children, should accompany measles control programmes in developing nations for maximum benefit from measles vaccination. HIV infection per se should not change measles vaccination programmes.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Age Factors; Antibodies; Biology; Child; Child Development; Child Nutrition; Delivery Of Health Care; Demographic Factors; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Growth; Health; Health Services; Hiv Infections; Immunity; Immunization; Immunologic Factors; Malnutrition; Measles; Nutrition; Nutrition Disorders; Physiology; Population; Population Characteristics; Primary Health Care; Research Report; Uganda; Vaccination; Viral Diseases; Youth

Mesh:

Substances:

Year:  1999        PMID: 10342701     DOI: 10.1093/ije/28.2.341

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  9 in total

1.  Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective.

Authors:  Emily R Smith; Emily E Rowlinson; Volga Iniguez; Kizee A Etienne; Rosario Rivera; Nataniel Mamani; Rick Rheingans; Maritza Patzi; Percy Halkyer; Juan S Leon
Journal:  Vaccine       Date:  2011-09-02       Impact factor: 3.641

Review 2.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

3.  Effect of multivitamin supplementation on measles vaccine response among HIV-exposed uninfected Tanzanian infants.

Authors:  Christopher R Sudfeld; Christopher Duggan; Alex Histed; Karim P Manji; Simin N Meydani; Said Aboud; Molin Wang; Edward L Giovannucci; Wafaie W Fawzi
Journal:  Clin Vaccine Immunol       Date:  2013-05-29

4.  Comparative Estimates of Crude and Effective Coverage of Measles Immunization in Low-Resource Settings: Findings from Salud Mesoamérica 2015.

Authors:  K Ellicott Colson; Paola Zúñiga-Brenes; Diego Ríos-Zertuche; Carlos J Conde-Glez; Marielle C Gagnier; Erin Palmisano; Dharani Ranganathan; Gulnoza Usmanova; Benito Salvatierra; Austreberta Nazar; Ignez Tristao; Emmanuelle Sanchez Monin; Brent W Anderson; Annie Haakenstad; Tasha Murphy; Stephen Lim; Bernardo Hernandez; Rafael Lozano; Emma Iriarte; Ali H Mokdad
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

Review 5.  The immune system in children with malnutrition--a systematic review.

Authors:  Maren Johanne Heilskov Rytter; Lilian Kolte; André Briend; Henrik Friis; Vibeke Brix Christensen
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

6.  Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis.

Authors:  Eleonora A M L Mutsaerts; Marta C Nunes; Martijn N van Rijswijk; Kerstin Klipstein-Grobusch; Diederick E Grobbee; Shabir A Madhi
Journal:  EClinicalMedicine       Date:  2018-07-02

7.  The role of polyclonal intravenous immunoglobulin in treating HIV-infected children with severe bacterial infections: a retrospective cohort study.

Authors:  Lyen C Huang; Landon Myer; Heather B Jaspan
Journal:  BMC Infect Dis       Date:  2008-09-24       Impact factor: 3.090

8.  HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization.

Authors:  Mathurin C Tejiokem; Ionela Gouandjika; Lydie Béniguel; Marie-Claire Endegue Zanga; Gilbert Tene; Jean C Gody; Elisabeth Njamkepo; Anfumbom Kfutwah; Ida Penda; Catherine Bilong; Dominique Rousset; Régis Pouillot; Frédéric Tangy; Laurence Baril
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

9.  Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.

Authors:  Sara Carazo; Marie-Noëlle Billard; Amélie Boutin; Gaston De Serres
Journal:  BMC Infect Dis       Date:  2020-03-29       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.